Volume 13, Number 10—October 2007
Dispatch
Ciprofloxacin-Resistant Neisseria meningitidis, Delhi, India
Table
Isolate | MIC (μg/mL) |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
PEN | CRO | RIF | CIP | GAT | MXF | LVX | SPX | NOR | NAL | |
SFDJ M-1 | 0.125 | 0.008 | 0.004 | 0.125 | 0.03 | 0.125 | 0.125 | 0.06 | 0.125 | >16 |
SFDJ M-2 | 0.125 | 0.008 | 0.004 | 0.25 | 0. 25 | 0.125 | 0.03 | 0.06 | 0.25 | >16 |
SFDJ 691 | 0.03 | <0.001 | 0.125 | 0.25 | 0.25 | 0.5 | 0.25 | 0.25 | 0.5 | >16 |
SFDJ 306 | 0.03 | 0.008 | 0.008 | 0.125 | 0.06 | 0.125 | 0.25 | 0.06 | 0.25 | >16 |
SFDJ 651 | 0.06 | 0.002 | 0.03 | 0. 5 | 0.125 | 0.25 | 0.25 | 0.125 | 0.5 | >16 |
SFDJ 568 | 0.125 | 0.002 | 0.06 | 0.25 | 0.125 | 0.25 | 0.25 | 0.125 | 0.5 | >16 |
SFDJ 668 | 0.06 | 0.002 | 0.06 | 0.25 | 0.125 | 0.25 | 0.125 | 0.125 | 0.25 | >16 |
SFDJ 270 | 0.125 | 0.008 | 0.015 | 0.125 | 0.06 | 0.125 | 0.125 | 0.125 | 0.25 | >16 |
SFDJ MA-3 | 0.06 | 0.004 | 0.125 | 0.5 | 0.25 | 0.25 | 1 | 1 | 1 | >16 |
SFDJ 339 | 0.125 | <0.001 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | >16 |
SFDJ 58 | 0.125 | 0.008 | 0.004 | 0.125 | 0.06 | 0.125 | 0.03 | 0.06 | 0.25 | >16 |
*PEN, penicillin; CRO, ceftriaxone; RIF, rifampin; CIP, ciprofloxacin; GAT, gatifloxacin; MFX, moxifloxacin; LVX, levofloxacin; SPX, sparfloxacin; NOR, norfloxacin; NAL, nalidixic acid.
Page created: July 02, 2010
Page updated: July 02, 2010
Page reviewed: July 02, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.